REPARE THERAPEUTICS INC (RPTX)
US7602731025 - Common Stock
REPARE THERAPEUTICS INC
NASDAQ:RPTX (12/20/2024, 8:00:01 PM)
After market: 1.33 +0.01 (+0.76%)1.32
0 (0%)
Company Profile
Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company is headquartered in St-Laurent, Quebec and currently employs 179 full-time employees. The company went IPO on 2020-06-19. The firm utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
Company Info
REPARE THERAPEUTICS INC
7210 Frederick-Banting, Suite 100
ST-LAURENT QUEBEC H4S 2A1
P: 18574127018
CEO: Lloyd M. Segal
Employees: 179
Website: https://www.reparerx.com/
RPTX News
9 days ago - ChartmillWhich stocks are moving on Friday?Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
9 days ago - ChartmillTop movers in Friday's sessionKeep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
9 days ago - Yahoo FinanceWhy Is Repare Therapeutics Stock Trading Lower On Friday?On Thursday, Repare Therapeutics Inc (NASDAQ:RPTX) revealed data from its MYTHIC Phase 1 gynecologic expansion trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) for endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers. As of the data cut-off date of November 14, 51 evaluable patients were enrolled in the gynecologic cancer expansion cohort of the MYTHIC trial. Across all tumor types treated at the optimized RP2D (n=67),
9 days ago - ChartmillThere are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
9 days ago - ChartmillTop movers in Friday's pre-market sessionDiscover the top movers in Friday's pre-market session and stay informed about market dynamics.
9 days ago - ChartmillThese stocks are moving in today's after hours sessionStay updated with the stocks that are on the move in today's after-hours session.
RPTX Twits
Here you can normally see the latest stock twits on RPTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
